Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine
203252032520325
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this …
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this … Continue reading "Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine"
The use of antimicrobial therapy in the field of cutaneous surgery can be a difficult and controversial topic. Overall, there are a lack of randomized controlled clinical trials evaluating the efficacy of antimicrobial prophylaxis within our field. As a result, much of the recommendations for antimicrobial prophylaxis are extrapolated from other fields, such as dentistry, cardiology, and orthopedi … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Watch as Dr. Han shares his tips for breaking into the conference circuit. Learn why it’s important to find your niche and the right mentor. Hear which meeting Dr. H … 
At ODAC 2023, we had the opportunity to learn about cicatricial alopecias from renowned dermatologist and hair expert Dr. Amy McMichael, Professor of Dermatology at Wake Forest University School of Medicine.
First, we considered a framework to check for cicatricial alopecias. This is particularly important because if we can identify cicatricial alopecia, we can make sure we are treating the rig … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 